Options Wonderland

[I Like Bottom Fishing]

ANDS News ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb Oral Presentation at 3:00 pm on October 31 at AASLD.

Saturday, October 30, 2010 9:01 AM

Scottrade.com
This email is compliments of Scottrade.com

News for 'ANDS' - (ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb Oral Presentation at 3:00 pm on October 31 at AASLD)

http://www.knobias.com/story.htm?eid=3.1.63228823af220672fa110e42660e608a9ed502011b0a170e3103304a64bbcf1d

http://www.knobias.com/individual/public/quote.htm?ticker=ANDS

SAN DIEGO, Oct 30, 2010 /PRNewswire via COMTEX/ -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) today announced the ANA598 data to be presented at the 61st
Annual Meeting of the American Association for the Study of Liver Disease
(AASLD) in Boston, MA. ANA598, the Company's direct-acting antiviral (DAA) being
developed for the treatment of hepatitis C, will be discussed in two
presentations at the conference:

On Sunday, October 31, 2010 at 3:00 pm Eastern Daylight Time, Eric Lawitz, M.D.,
a principal investigator of the study, will give an oral presentation titled,
"Safety and Antiviral Activity of ANA598 in Combination with Pegylated
Interferon alpha 2A Plus Ribavirin in Treatment-Naive Genotype-1 Chronic HCV
Patients." The slides will be available on the Company's website at
www.anadyspharma.com following conclusion of the presentation.

On Tuesday, November 2, 2010 at 7:00 am Eastern Daylight Time, Anadys will
present data in a poster titled, "IL28B Polymorphism and Kinetics of Antiviral
Activity for ANA598 in Combination with Pegylated Interferon alpha 2A Plus
Ribavirin in Treatment-Naive Genotype-1 Chronic HCV Patients." The poster will
be available on the Company's website at www.anadyspharma.com.

"We are pleased with the positive clinical profile seen to date for ANA598, as
well as its preclinical properties that support investigation of combinations
with other direct antivirals," said James L. Freddo, M.D., Senior Vice
President, Drug Development and Chief Medical Officer of Anadys. "In the
upcoming Phase IIb study, we look forward to testing ANA598 for the first time
in treatment-experienced patients, as well as in a larger population of
treatment-naive patients."

In the oral presentation, data from an ongoing Phase II combination study show
that ANA598 added to pegylated interferon and ribavirin (current standard of
care, or SOC) accelerated the rate of patients achieving undetectable levels of
virus compared to placebo plus SOC, and that the antiviral response was
equivalent at 200 mg bid and 400 mg bid ANA598. The data from the study further
show a durable antiviral response through 12 weeks, with only a single patient
(<2% of patients in the ANA598 arms) experiencing viral breakthrough while
receiving ANA598 plus SOC. The safety profile of ANA598 through 12 weeks was
excellent in the study, with reported adverse events being typical for patients
treated with interferon and ribavirin alone, and the incidence of rash in
patients receiving ANA598 200 mg bid plus SOC in the study was comparable to the
group receiving placebo plus SOC.

Additional data from the Phase II combination study will be presented reflecting
the persistence of ANA598's benefit beyond week 12. 39 of 41 patients (>95%) who
achieved undetectable levels of virus at week 12 in the two active arms have
maintained undetectable levels while continuing to receive SOC through the
latest available measurements. For patients who, per protocol, concluded all
treatment at week 24, interim analysis of SVR data for available patients
indicates that 8 of 11 patients maintained undetectable levels of virus 12 weeks
later, referred to as a Sustained Virological Response 12, or SVR12. The three
patients who relapsed after concluding treatment at week 24 demonstrated the
lowest week 4 ribavirin levels of all patients who concluded treatment at week
24, consistent with the known impact of ribavirin levels on converting
on-treatment response to SVR. Data is available for three patients 24 weeks
after concluding treatment. All three patients achieved an SVR24, recognized as
a viral cure.

In the poster presentation on Tuesday, November 2, 2010, Anadys will present
additional data from the Phase II combination study showing that the addition of
ANA598 to SOC conferred benefit independent of a patient's IL-28B genotype. In
patients with the IL-28B genotype most responsive to SOC (referred to as CC),
ANA598 accelerated the rate of achieving undetectable levels of virus, with 82%
of patients who received ANA598 plus SOC achieving undetectable levels by week
4, compared to 27% of patients who received placebo plus SOC. In patients with
IL-28B genotypes less responsive to SOC (referred to as CT and TT, or
collectively non-CC), ANA598 both accelerated the rate of achieving undetectable
levels of virus and increased the percentage of patients with undetectable
levels of virus at week 12. In the non-CC patients, 38% of patients who received
ANA598 plus SOC achieved undetectable levels of virus by week 4, compared to 8%
of patients who received placebo plus SOC, and 73% of patients who received
ANA598 plus SOC achieved undetectable levels of virus at week 12, compared to
47% of patients who received placebo plus SOC.

Phase II Combination Study

In the ongoing Phase II study, approximately 90 treatment-naive genotype 1 HCV
patients have received ANA598 or placebo in combination with Pegasys(R)
(peginterferon alfa-2a) and Copegus(R) (ribavirin, USP) for 12 weeks at dose
levels of 200 mg twice-daily (bid) or 400 mg bid, each with a loading dose of
800 mg bid on day one. After week 12, patients are to continue receiving SOC.
Patients who achieved undetectable levels of virus at weeks 4 and 12 were
randomized to stop all treatment at week 24 or 48. The primary endpoint of the
study is the proportion of patients who achieve undetectable levels of virus at
week 12 (defined as complete Early Virological Response, or cEVR). Additional
endpoints include safety and tolerability as well as the proportion of patients
with undetectable levels of virus at week 4 (defined as Rapid Virological
Response, or RVR). Patients are being followed for 24 weeks after stopping
therapy to determine the rate of Sustained Virological Response, or SVR.
Approximately 90 patients have been enrolled in this study - with approximately
30 patients receiving ANA598 plus SOC at each dose level and 30 patients
receiving placebo plus SOC. The study is being managed by the Duke Clinical
Research Institute (DCRI) and is being conducted at a number of clinical sites
in the United States.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to
improving patient care by developing novel medicines for the treatment of
hepatitis C. The Company believes hepatitis C represents a large unmet medical
need in which meaningful improvements in treatment outcomes may be attainable
with the introduction of new medicines. Anadys is preparing to initiate a Phase
IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to
current standard of care for the treatment of hepatitis C. The Company is also
preparing to resume clinical development of ANA773, the Company's oral,
small-molecule inducer of endogenous interferons that acts via the Toll like
receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature
constitute "forward-looking statements." Such statements include, but are not
limited to, references to (i) the plans and trial design for the planned ANA598
Phase IIb study; (ii) the belief that the preclinical properties of ANA598
support investigation of combinations with other direct antivirals and the
ability to pursue such combinations; (iii) assessments of the potency, safety
and tolerability profile of ANA598 based on the 12 week results; (iv) the
durability of antiviral response after treatment with ANA598 is concluded as
well as interim SVR rates based on data available to date; and (v) the
beneficial effect of ANA598 in both CC and non-CC patients based on observations
in the Phase II combination study. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors, which may cause Anadys'
actual results to be materially different from historical results or from any
results expressed or implied by such forward-looking statements. For example,
the results of preclinical and early clinical studies may not be predictive of
future results, and Anadys cannot provide any assurances that ANA598 or ANA773
will not have unforeseen safety issues, will have favorable results in future
clinical trials or will receive regulatory approval. In addition, Anadys'
results may be affected by competition from other biotechnology and
pharmaceutical companies, its effectiveness at managing its financial resources,
its ability to enter into transactions around its product candidates, its
ability to successfully develop and market products, difficulties or delays in
its preclinical studies or clinical trials, difficulties or delays in
manufacturing its clinical trials materials, the scope and validity of patent
protection for its products, regulatory developments and its ability to obtain
additional funding to support its operations. Risk factors that may cause actual
results to differ are more fully discussed in Anadys' SEC filings, including
Anadys' Form 10-K for the year ended December 31, 2009, Form 10-Q for the
quarter ended September 30, 2010 and Form 8-K filed on October 15, 2010. All
forward-looking statements are qualified in their entirety by this cautionary
statement. Anadys is providing this information as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or otherwise.

Pegasys(R) and Copegus(R) are registered trademarks of Hoffman-La Roche Inc.

SOURCE Anadys Pharmaceuticals, Inc.

www.prnewswire.com


Copyright (C) 2010 PR Newswire. All rights reserved

-0-

KEYWORD: California

Massachusetts

INDUSTRY KEYWORD: PHA

MTC

HEA

BIO

SUBJECT CODE: TDS

TRI

http://www.knobias.com/story.htm?eid=3.1.63228823af220672fa110e42660e608a9ed502011b0a170e3103304a64bbcf1d

Source: Comtext Market News